title: [Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy].
abstract: OBJECTIVE
  Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL.
  
  
  METHODS
  HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir.
  
  
  RESULTS
  The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL.
  
  
  CONCLUSIONS
  Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.
authors.affiliation: Universidade Federal de Juiz de Fora, Departamento de Gastroenterologia, Juiz de Fora, MG, Brazil.
authors.forename: Raíssa Neves
authors.initials: RN
authors.lastname: Fagundes
authors.affiliation: Universidade Federal de Juiz de Fora, Departamento de Gastroenterologia, Juiz de Fora, MG, Brazil.
authors.forename: Lincoln Eduardo Villela Vieira de Castro
authors.initials: LE
authors.lastname: Ferreira
authors.affiliation: Universidade Federal de Juiz de Fora, Departamento de Gastroenterologia, Juiz de Fora, MG, Brazil.
authors.forename: Fábio Heleno de Lima
authors.initials: FH
authors.lastname: Pace
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000008:administration & dosage; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009842:Oligopeptides; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C486464:telaprevir; C417083:peginterferon alfa-2b